<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41608">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02564718</url>
  </required_header>
  <id_info>
    <org_study_id>17618</org_study_id>
    <secondary_id>2015-000962-76</secondary_id>
    <nct_id>NCT02564718</nct_id>
  </id_info>
  <brief_title>Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates</brief_title>
  <acronym>Einstein Jr</acronym>
  <official_title>7-day Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Children From Birth to Less Than 6 Months With Arterial or Venous Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Pharmaceuticals Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether rivaroxaban is safe and effective to use in
      children age newborn to less than 6 months and how long it stays in the body and how it is
      used in the body. Safety will be assesed by looking at the incidence and types of bleeding
      events. There will also be a check for worsening of blood clots.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neonates and infants aged less than 6 months who pass the screen of in- and exclusion
      criteria, who have been treated for at least five days with heparin and /or VKA for
      confirmed symptomatic or asymptomatic arterial or venous thrombosis are eligible for the
      study. Study treatment consists of a 7-day treatment with an age- and body weight-adjusted
      twice daily oral rivaroxaban dosing to achieve a similar exposure as that observed in adults
      treated for venous thromboembolism (VTE) with 20 mg rivaroxaban once daily. Rivaroxaban will
      be provided as granules for preparation of an oral suspension (1 mg/mL after re-suspension)
      using a b.i.d. regimen with 12-hour intervals. An ultrasound will be performed before
      starting rivaroxaban at treatment day 1 and after the end of rivaroxaban treatment at day 8.
      The last dose of rivaroxaban treatment will be followed by a 30-day post study treatment
      period, regardless of the duration of study drug administration. After cessation of
      rivaroxaban, it is at the investigator's discretion to continue with anticoagulants. The
      principal safety outcome is the combination of major and clinically relevant non-major
      bleeding. The efficacy outcome is the composite of all symptomatic recurrent thromboembolism
      and asymptomatic deterioration in thrombotic burden on repeat imaging. All suspected
      recurrent thromboembolism, asymptomatic deterioration in thrombotic burden on repeat
      imaging, deaths, as well as all episodes of bleeding will be evaluated by a CIAC.
      Adjudication results will be the basis for the final analyses.

      For all children, visits are scheduled at regular time points (see Table 1). Enrolled
      children who are not treated or those with premature discontinuation of rivaroxaban will at
      least be seen at the end of the study treatment period. During all contacts, the treatment
      and clinical course of the child will be evaluated. Children with suspected efficacy or
      safety outcomes will undergo confirmatory testing as per standard of care. Blood samples for
      PK/PD will be taken at defined time points (see Table 2).

      An Independent Data Monitoring Committee (DMC) will monitor the children's safety during the
      study and give recommendations to the steering committee.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2015</start_date>
  <completion_date type="Anticipated">December 29, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 29, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma concentration of rivaroxaban</measure>
    <time_frame>Day 1- 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>rivaroxaban protime (PT)</measure>
    <time_frame>Day 1- 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>activated partial thromboplastin time (aPPT)</measure>
    <time_frame>Day 1- 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>anti-factor Xa activity(anti-Xa) activity in the course of time after rivaroxaban dosing</measure>
    <time_frame>Day 1-8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of major bleeding</measure>
    <time_frame>At day 1-7</time_frame>
    <description>Assessed by independent adjudication committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically relevant non-major bleeding</measure>
    <time_frame>At day 1-7</time_frame>
    <description>Assessed by independent adjudication committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of symptomatic recurrent thromboembolism</measure>
    <time_frame>At day 1-7</time_frame>
    <description>Assessed by independent adjudication committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of asymptomatic deterioration in thrombotic burden on repeat imaging</measure>
    <time_frame>At day 8</time_frame>
    <description>Assessed by independent adjudication committee. Comparison of baseline thrombosis imaging test with mandatory repeat imaging test at day 8 to identify subjects with worsening of the thrombosis at day 8</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban oral suspension from granules will be dosed according to body weight as oral 0.1% suspension (1 mg/mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban(Xarelto,BAY59-7939)</intervention_name>
    <description>Body weight adjusted dosing of rivaroxaban to achieve a similar exposure in the range as that observed in adults treated for venour thromboembolism (VTE) with 20 mg once daily.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children from birth to less than 6 months with documented symptomatic or asymptomatic
             venous or arterial thrombosis who have been treated with anticoagulant therapy for at
             least 5 days.

          -  Gestational age at birth of at least 37 weeks.

          -  Hemoglobin, platelets, creatinine, ALT and total and direct bilirubin assessed within
             10 days prior to enrollment.

          -  Oral feeding/nasogastric/gastric feeding for at least 10 days.

          -  Informed consent provided.

          -  Body weight &gt;2600 g

        Exclusion Criteria:

          -  Active bleeding or high risk for bleeding contraindicating anticoagulant therapy,
             including history of intra-ventricular bleeding.

          -  Symptomatic progression of thrombosis during preceding anticoagulant treatment.

          -  Planned invasive procedures, including lumbar puncture and removal of nonperipherally
             placed central lines during study treatment.

          -  Hepatic disease which is associated with either: coagulopathy leading to a clinically
             relevant bleeding risk, or alanine aminotransferase (ALT) &gt; 5x upper level of normal
             (ULN) or total bilirubin (TB) &gt; 2x ULN with direct bilirubin &gt; 20% of the total.

          -  Creatinine &gt;1.5 times of normal.

          -  Uncontrolled Hypertension defined as &gt;95th percentile.

          -  History of gastrointestinal disease or surgery associated with impaired absorption.

          -  Platelet count &lt;100 x 109/L.

          -  Concomitant use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 (CYP3A4)
             and P-glycoprotein (P-gp), e.g. all human immunodeficiency virus protease inhibitors
             and the following azole-antimycotics agents: ketoconazole, itraconazole,
             voriconazole, posaconazole, if used systemically (fluconazole is allowed)

          -  Concomitant use of strong inducers of CYP3A4, e.g. rifampicin, rifabutin,
             phenobarbital, phenytoin and carbamazepine

          -  Indication for anticoagulant therapy other than current thrombosis.

          -  Indication for antiplatelet therapy or non-steroid anti-inflammatory drug (NSAID)
             therapy. Incidental use is allowed.

          -  Hypersensitivity to rivaroxaban or its excipients.

          -  Participation in a study with an investigational drug or medical device within 30
             days prior to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-6089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <zip>34059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Darmstadt</city>
        <state>Hessen</state>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <zip>91052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Haemek Medical Center</name>
      <address>
        <city>AFula</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat Gan</city>
        <zip>5262000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Esplugues de LLobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Izmir</city>
        <zip>35-100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 7, 2017</lastchanged_date>
  <firstreceived_date>September 4, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
